FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046907366> ?p ?o ?g. }

• W2046907366 endingPage "243" @default.
• W2046907366 startingPage "243" @default.
• W2046907366 abstract "See “Autoantibodies and Autoimmune Disease During Treatment of Children With Chronic Hepatitis C” by Molleston et al on page 304. Autoantibody reactivity is a common occurrence in liver diseases. As in other liver diseases, chronic hepatitis C is associated with the presence of various autoimmune markers and autoimmune disease. This autoantibody reactivity in turn may be a reflection of immune system activation. Molecular mimicry of viral antigens by self-antigens, chronic stimulation of B cells, and a bystander effect are some proposed mechanisms for the development of autoimmune phenomena in hepatitis C (1). The development of autoantibodies and autoimmune diseases is a recognized adverse effect of interferon therapy in adults (2); however, it is unclear whether interferon unmasks previously unrecognized autoimmune disease or causes de novo autoimmune disease. Interestingly, some studies report an association between baseline autoantibody levels and hepatitis C virus (HCV) treatment response in adults (3). In this issue of the Journal of Pediatric Gastroenterology and Nutrition, Molleston et al (4) analyzed autoantibodies in stored serum from the PEDS-C (Pegylated Interferon +/− Ribavarin for Children With Hepatitis C) trial. Autoantibodies were present in 19% of the children at baseline, with a nonsignificant upward trend in prevalence during the course of treatment. These autoantibodies were not predictive of treatment outcome, treatment adverse effects, or alanine aminotransferase elevations during treatment. Because the PEDS-C trial excluded children with evidence of preexisting autoimmune diseases, we cannot determine whether interferon worsened preexisting autoimmune disorders; however, the PEDS-C population was well suited for the assessment of de novo development of autoimmune disease. This occurred in 3 of 114 children, 2 of whom developed autoantibodies while receiving peginterferon. The scant data that are available suggest the presence of a positive anti-nuclear antibody (ANA) in approximately 6% to 15% of healthy controls (5). This is comparable with the ANA positivity rate in the PEDS-C cohort before treatment. The present study sheds light on an aspect of pediatric hepatitis C that has been largely unexplored until present. Molleston et al were able to measure changes in autoantibodies during the course of HCV therapy in a well-characterized cohort of children. They determined that autoantibodies did not correlate with alanine aminotransferase, and probably are not mere markers of inflammation. They also did not find a relation between autoantibodies and response to therapy, showing that the prognostic value reported in adults did not hold in this population. In addition, the authors determined the incidence of de novo autoimmune disease with HCV treatment. Furthermore, these findings are particularly timely. With the advent of new directly acting antivirals, the end of the interferon era may be imminent, making it less feasible to study the effect of exogenous interferon on autoantibody reactivity. Thus, the present study adds to our understanding at an opportune moment in pediatric hepatology. For the practitioner, this article shows that if preexisting autoimmune disease has been excluded, one need not check routinely for autoantibodies during therapy in the absence of symptoms. The findings reported in this issue of the Journal of Pediatric Gastroenterology and Nutrition are a major contribution, and the area of autoimmunity in pediatric HCV is in its nascent stages. Additional data from large cohorts, advances in immunology, and improved autoantibody tests will enhance our understanding of chronic hepatitis C and its myriad manifestations." @default.
• W2046907366 created "2016-06-24" @default.
• W2046907366 creator A5030298276 @default.
• W2046907366 creator A5068960425 @default.
• W2046907366 date "2013-03-01" @default.
• W2046907366 modified "2023-09-25" @default.
• W2046907366 title "Autoantibodies in Hepatitis C" @default.
• W2046907366 cites W2023702382 @default.
• W2046907366 cites W2085737748 @default.
• W2046907366 cites W2126179499 @default.
• W2046907366 cites W2158412309 @default.
• W2046907366 doi "https://doi.org/10.1097/mpg.0b013e3182774b04" @default.
• W2046907366 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3584299" @default.
• W2046907366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23443062" @default.
• W2046907366 hasPublicationYear "2013" @default.
• W2046907366 type Work @default.
• W2046907366 sameAs 2046907366 @default.
• W2046907366 citedByCount "1" @default.
• W2046907366 countsByYear W20469073662015 @default.
• W2046907366 crossrefType "journal-article" @default.
• W2046907366 hasAuthorship W2046907366A5030298276 @default.
• W2046907366 hasAuthorship W2046907366A5068960425 @default.
• W2046907366 hasBestOaLocation W20469073661 @default.
• W2046907366 hasConcept C159047783 @default.
• W2046907366 hasConcept C159654299 @default.
• W2046907366 hasConcept C163764329 @default.
• W2046907366 hasConcept C203014093 @default.
• W2046907366 hasConcept C2776029263 @default.
• W2046907366 hasConcept C71924100 @default.
• W2046907366 hasConceptScore W2046907366C159047783 @default.
• W2046907366 hasConceptScore W2046907366C159654299 @default.
• W2046907366 hasConceptScore W2046907366C163764329 @default.
• W2046907366 hasConceptScore W2046907366C203014093 @default.
• W2046907366 hasConceptScore W2046907366C2776029263 @default.
• W2046907366 hasConceptScore W2046907366C71924100 @default.
• W2046907366 hasIssue "3" @default.
• W2046907366 hasLocation W20469073661 @default.
• W2046907366 hasLocation W20469073662 @default.
• W2046907366 hasLocation W20469073663 @default.
• W2046907366 hasLocation W20469073664 @default.
• W2046907366 hasLocation W20469073665 @default.
• W2046907366 hasOpenAccess W2046907366 @default.
• W2046907366 hasPrimaryLocation W20469073661 @default.
• W2046907366 hasRelatedWork W129921508 @default.
• W2046907366 hasRelatedWork W1993268753 @default.
• W2046907366 hasRelatedWork W2058737939 @default.
• W2046907366 hasRelatedWork W2063966917 @default.
• W2046907366 hasRelatedWork W2089465242 @default.
• W2046907366 hasRelatedWork W2134281733 @default.
• W2046907366 hasRelatedWork W2405445121 @default.
• W2046907366 hasRelatedWork W2412733333 @default.
• W2046907366 hasRelatedWork W358617856 @default.
• W2046907366 hasRelatedWork W70023833 @default.
• W2046907366 hasVolume "56" @default.
• W2046907366 isParatext "false" @default.
• W2046907366 isRetracted "false" @default.
• W2046907366 magId "2046907366" @default.
• W2046907366 workType "article" @default.